Search clinical trials for: BIAP

Total 545 results

Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease
Sunovion

Withdrawn

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

Epilepsy

United States
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
Novo Nordisk A/S

Completed

An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes (SAFE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Philippines
Centre Hospitalier Universitaire de Besancon

Unknown

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (PAACS)

Septic Shock

France
University of Patras

Completed

Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease

Coronary Artery Disease | Endothelial Function

Greece
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

HIV Infections | Kidney Diseases

United States
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
University of Trieste

Completed

Hypovitaminosis D and "Metabolic" Inflammatory Status in Patients With Obesity (ViDO)

Obesity | Hypovitaminosis D

Italy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.
Covance

Completed

Effect of BIA 5 1058 on Cardiac Repolarization

Heart Failure | Cardiovascular Disease | Pulmonary Arterial Hypertension

United Kingdom
The Immunobiological Technology Institute (Bio-Manguinhos)...
Hospital de Clinicas de Porto Alegre

Unknown

BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (BIP48II/III)

Chronic Hepatitis C

Brazil
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Tongji Hospital
Shanghai Children's Hospital

Completed

Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy

Treatment Compliance | Cholangitis, Secondary Biliary | Antibodies Drug Specific

China
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
National Institute of Mental Health (NIMH)
University of Oregon; University of Maryland; University of Minnesota

Recruiting

Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

Anxiety Disorders | Major Depressive Disorder

United States
Sunovion

Completed

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Epilepsy With Partial On-set Seizures

United States, Canada
St. Antonius Hospital
UMC Utrecht; Leiden University Medical Center; Medical Centre Leeuwarden; Rijnstate... and other collaborators

Unknown

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly (POPular AGE)

Unstable Angina | Non-ST-elevation Acute Coronary Syndrome | Non-ST-elevation Myocardial Infarction

Netherlands
Hospital Sant Joan de Deu
Fundació Sant Joan de Déu; Spanish National Health System

Completed

Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation

Inflammatory Response | Multi-organ Failure

Spain
UNC Lineberger Comprehensive Cancer Center

Recruiting

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

Cancer | Malignant Neoplasm

United States
N.N. Petrov National Medical Research Center of...
The Foundation for Cancer Research Support (RakFond)

Recruiting

Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery (MACS)

Bladder Cancer

Russian Federation
Pennington Biomedical Research Center
Tanita

Completed

Tanita BIA System Validation (Tanita)

Body Composition | Circumference Measurements | Tissue Thickness Measurements

United States
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Seagen Inc.

Withdrawn

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Hematopoietic/Lymphoid Cancer

United States
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

Epilepsy
Novo Nordisk A/S

Completed

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (Mix2Mix)

Diabetes Mellitus, Type 2 | Diabetes

Belgium, Luxembourg
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Withdrawn

Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease

Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Recruiting

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma

United States
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Boehringer Ingelheim

Completed

Antihypertensive Medications and the Risk of Sepsis

Hypertension
University of British Columbia
Post Graduate Institute of Medical Education and Research, Chandigarh

Unknown

Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma

Asthma in Children | Asthma Acute
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal

3

Subscribe